Document:

Amendment to Employment Agreement

 EXHIBIT 10.2 
 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 
 BETWEEN JACK W. CALLICUTT AND CORAUTUS GENETICS, INC.

 This FIRST AMENDMENT to that certain EMPLOYMENT AGREEMENT between Corautus Genetics, Inc. (the “Company”) and Jack W.
Callicutt (the “Executive”) dated October 1, 2005 (the “Agreement”) is hereby entered into by and between the Company and the Executive effective as of the 15th day of May, 2006. 
 W I T N E S S E T H: 
 WHEREAS,
the Company and the Executive are parties to the Agreement; and 
 WHEREAS, due to the precipitous drop in the value of the stock
of the Company following the termination of the enrollment of patients in the GENASIS Phase IIb Clinical Trial in April 2006, the Company has deemed it necessary to provide the Executive with incentives to continue in the employ of the Company; and

 WHEREAS, the Board of Directors of the Company approved this amendment to the Agreement to include certain retention incentives to
encourage the Executive to continue his employment with the Company, to increase the likelihood of retaining the Executive and to create stability within the Company; 
 NOW, THEREFORE, effective as of May 15, 2006, the parties hereby amend the Agreement as follows: 
 1. A new
Article 7 shall be added to the Agreement to read as follows: 
 “ARTICLE 7 
 RETENTION INCENTIVES 
 7.1 Cash
Retention Payment. The Executive shall be entitled to receive a lump sum cash payment of $35,000 if he is employed by the Company on September 30, 2006. The Executive shall be entitled to receive an additional lump sum cash payment of
$35,000 if he is employed by the Company on March 31, 2007. If the Executive is employed on the date(s) provided herein, the cash payment(s) shall be paid to the Executive no later than the next regularly scheduled payroll date following the
date the Executive becomes entitled to such payment. 
 7.2 Nonqualified Stock Option Award. In accordance with and subject to
the terms of the Corautus Genetics Inc. 2002 Stock Plan (the “Plan”), the Company agrees to grant to the Executive nonqualified stock options to purchase 80,000 shares of the Company’s 

 
common stock according to the following terms and conditions (any additional terms and conditions of such option grant to be as specified in the option
agreement): 
 (a) The date of grant shall be the effective date of this First Amendment to the Agreement; 
 (b) The per share option exercise price shall be the fair market value per share (as defined in the Plan) on the date of grant; 
 (c) The options shall become exercisable as follows: 
 (i) 40,000 of the option shares shall become exercisable on March 31, 2007 if the Executive is employed by the Company on that date; and 
 (ii) The remaining 40,000 option shares shall become exercisable on March 31, 2008 if the Executive is employed by the Company on that date. 
 (d) The options shall have a 10-year term and, except as specified herein, shall be subject to the terms and provisions of the Plan; and 
 (e) Once exercisable, the options shall remain exercisable following termination of employment only as provided under the terms of the Plan.”

 2. Except as specifically provided above, the terms of the Agreement shall remain in full force and effect as prior to this First Amendment. 

IN WITNESS WHEREOF, the Executive and the Company have executed and delivered this First Amendment to the Agreement as of the date set forth
above, but actually on the date set forth below. 
  

			
	CORAUTUS GENETICS, INC.
		
	By:	 	 /s/ Richard E. Otto

		 	Richard E. Otto
		 	President and CEO
		
	Date:	 	May 15, 2006
	
	JACK W. CALLICUTT
	
	 /s/ Jack W. Callicutt

		
	Date:	 	May 15, 2006Amendment to Employment Agreement

 EXHIBIT 10.3 
 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 
 BETWEEN MICHAEL K. STEELE AND CORAUTUS GENETICS, INC.

 This FIRST AMENDMENT to that certain EMPLOYMENT AGREEMENT between Corautus Genetics, Inc. (the “Company”) and Michael K.
Steele (the “Executive”), originally effective as of May 1, 2005 and as renewed effective May 1, 2006 (the “Agreement”), is hereby entered into by and between the Company and the Executive effective as of the 15th day of May,
2006. 
 W I T N E S S E T H: 
 WHEREAS, the Company and the Executive are parties to the Agreement; and 
 WHEREAS, due to the precipitous drop in
the value of the stock of the Company following the termination of the enrollment of patients in the GENASIS Phase IIb Clinical Trial in April 2006, the Company has deemed it necessary to provide the Executive with incentives to continue in the
employ of the Company; and 
 WHEREAS, the Board of Directors of the Company approved this amendment to the Agreement to include
certain retention incentives to encourage the Executive to continue his employment with the Company, to increase the likelihood of retaining the Executive and to create stability within the Company; 
 NOW, THEREFORE, effective as of May 15, 2006, the parties hereby amend the Agreement as follows: 
 1. A new Article 7 shall be added to the Agreement to read as follows: 
 “ARTICLE 7 
 RETENTION INCENTIVES 
 7.1 Cash Retention Payment. The Executive shall be entitled to receive a lump sum cash payment of $25,000 if he is employed by the Company
on September 30, 2006. The Executive shall be entitled to receive an additional lump sum cash payment of $25,000 if he is employed by the Company on March 31, 2007. If the Executive is employed on the date(s) provided herein, the cash
payment(s) shall be paid to the Executive no later than the next regularly scheduled payroll date following the date the Executive becomes entitled to such payment. 
 7.2 Nonqualified Stock Option Award. In accordance with and subject to the terms of the Corautus Genetics Inc. 2002 Stock Plan (the “Plan”), the Company agrees to grant to the Executive
nonqualified stock options to purchase 60,000 shares of the Company’s 

 
common stock according to the following terms and conditions (any additional terms and conditions of such option grant to be as specified in the option
agreement): 
 (a) The date of grant shall be the effective date of this First Amendment to the Agreement; 
 (b) The per share option exercise price shall be the fair market value per share (as defined in the Plan) on the date of grant; 
 (c) The options shall become exercisable as follows: 
 (i) 30,000 of the option shares shall become exercisable on March 31, 2007 if the Executive is employed by the Company on that date; and 
 (ii) The remaining 30,000 option shares shall become exercisable on March 31, 2008 if the Executive is employed by the Company on that date. 
 (d) The options shall have a 10-year term and, except as specified herein, shall be subject to the terms and provisions of the Plan; and 
 (e) Once exercisable, the options shall remain exercisable following termination of employment only as provided under the terms of the Plan.”

 2. Except as specifically provided above, the terms of the Agreement shall remain in full force and effect as prior to this First Amendment. 

IN WITNESS WHEREOF, the Executive and the Company have executed and delivered this First Amendment to the Agreement as of the date set forth
above, but actually on the date set forth below. 
  

			
	CORAUTUS GENETICS, INC.
		
	By:	 	 /s/ Richard E. Otto

		 	Richard E. Otto
		 	President and CEO
		
	Date:	 	May 15, 2006
	
	MICHAEL K. STEELE
	
	 /s/ Michael K. Steele

		
	Date:	 	May 15, 2006Amendment to Employment Agreement

 EXHIBIT 10.4 
 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT 
 BETWEEN RICHARD E. OTTO AND CORAUTUS GENETICS, INC.

 This FIRST AMENDMENT to that certain EMPLOYMENT AGREEMENT between Corautus Genetics, Inc. (the “Company”) and Richard E.
Otto (the “Executive”) dated February 4, 2005 (the “Agreement”) is hereby entered into by and between the Company and the Executive, effective as of the 21st day of June, 2006. 
 W I T N E S S E T H: 
 WHEREAS,
the Company and the Executive are parties to the Agreement; and 
 WHEREAS, the Executive’s Agreement expires as of
February 3, 2007, and the Company desires to amend the Executive’s Agreement to extend the term of the Agreement until March 31, 2007; and 
 WHEREAS, to provide incentives for the Executive to extend the term of the Agreement and to attain certain other milestones, the Company desires to provide for a cash retention payment of $115,000 if the
Executive is employed on January 31, 2007 and to grant options to the Executive to purchase shares of the common stock of the Company to become exercisable upon the achievement of those certain milestones on or before March 31, 2007; and

 WHEREAS, the Board of Directors of the Company has approved the amendment of the Agreement; 
 NOW, THEREFORE, effective as of June 21, 2006, the parties hereby amend the Agreement as follows: 
 1. The first sentence of Article 2 of the Agreement shall be amended to read as follows: 
 “Unless terminated earlier as provided in Article 4, this Agreement shall extend until March 31, 2007.” 
 2.
A new Article 7 shall be added to the Agreement to read as follows: 
 “ARTICLE 7 
 RETENTION INCENTIVES 
 7.1 Cash
Retention Payment. The Executive shall be entitled to receive a lump sum cash payment of $115,000 on January 31, 2007, if he is employed by the Company on that date. If the Executive is employed on January 31, 2007, as provided
herein, the cash payment shall be paid to the Executive no later than the next regularly scheduled payroll date following the date the Executive becomes entitled to such payment. 

 7.2 Nonqualified Stock Option Award. In accordance with and subject to the terms of the
Corautus Genetics Inc. 2002 Stock Plan (the “Plan”), as of the effective date of this First Amendment to the Agreement, the Executive shall be entitled to a grant of nonqualified stock options to purchase 200,000 shares of the
Company’s common stock at a per share exercise price equal to the fair market value of the Company’s common stock on June 21, 2006, subject to the terms and conditions approved by the Company and set forth in a nonqualified stock
option agreement.” 
 3. Except as specifically provided above, the terms of the Agreement shall remain in full force and effect as prior to this First
Amendment. 
 IN WITNESS WHEREOF, the Executive and the Company have executed and delivered this First Amendment to the Agreement as
of the date set forth above, but actually on the date set forth below. 
  

			
	CORAUTUS GENETICS, INC.
		
	By:	 	 /s/ James C. Gilstrap

		 	James C. Gilstrap
		 	Chairman of the Board of Directors
		
	Date:	 	June 21, 2006
	
	RICHARD E. OTTO
	
	 /s/ Richard E. Otto

		
	Date:	 	June 21, 2006

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]